New drug cocktail aims to stop cervical cancer return
Disease control
Not yet recruiting
This phase II trial tests whether adding pembrolizumab and lenvatinib to standard chemoradiation and brachytherapy can improve outcomes for adults with high-risk locally advanced cervical cancer. About 87 participants will receive the drug combination and be followed for two year…
Phase: PHASE2 • Sponsor: Prof. Dr. Remi A. Nout • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC